AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20122576 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 103
Study 17415136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT) with radiosurgery (RF)
Number of subjects: 114
Study 17415136 — intervention group
Group type: COMPARATOR
Intervention: Cold tonsillectomy (TE)
Number of subjects: 114
Study 16118720 — intervention group
Group type: EXPERIMENTAL
Intervention: AmniSure rapid immunoassay
Number of subjects: 203
Study 16118720 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic methods
Number of subjects: 203
Study 12165574 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (400 micro g every 8 hours up to 4 doses)
Number of subjects: 62
Study 12165574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 10064126 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone analogue (2.5 mg Livial) plus 800 mg calcium
Number of subjects: 33
Study 10064126 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 800 mg calcium
Number of subjects: 33
Study 7495600 — intervention group
Group type: COMPARATOR
Intervention: Moderately active participants
Number of subjects: 2004
Study 7495600 — intervention group
Group type: COMPARATOR
Intervention: Very active participants
Number of subjects: 2004
Study 7495600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary participants
Number of subjects: 2004
Study 31873286 — intervention group
Group type: EXPERIMENTAL
Intervention: Population activity decoding of likelihood function from visual cortex during categorization task
Number of subjects: 0
Study 30935369 — intervention group
Group type: EXPERIMENTAL
Intervention: TSEipcw (Two-stage estimation with inverse probability of censoring weights)
Number of subjects: 0
Study 30935369 — intervention group
Group type: COMPARATOR
Intervention: Re-censoring
Number of subjects: 0
Study 30935369 — intervention group
Group type: COMPARATOR
Intervention: Non-re-censoring
Number of subjects: 0
Study 27855463 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women (339)
Number of subjects: 1669
Study 27855463 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 3 obese women (69)
Number of subjects: 1669
Study 27855463 — intervention group
Group type: COMPARATOR
Intervention: Nonobese women (1261)
Number of subjects: 1669
Study 25573070 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic Vestibular Stimulation (SVS)
Number of subjects: 10
Study 25573070 — intervention group
Group type: EXPERIMENTAL
Intervention: LDOPA
Number of subjects: 10
Study 25573070 — intervention group
Group type: EXPERIMENTAL
Intervention: SVS combined with LDOPA
Number of subjects: 10
Study 25573070 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 10
Study 23711727 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive Listening Device (ALD) during structured conversation task
Number of subjects: 22
Study 23711727 — intervention group
Group type: COMPARATOR
Intervention: No Assistive Listening Device (ALD) during structured conversation task
Number of subjects: 22
Study 23711727 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-hearing groups
Number of subjects: 22
Study 23711727 — intervention group
Group type: COMPARATOR
Intervention: Self-perceived hearing handicap
Number of subjects: 22
Study 21350719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation program
Number of subjects: 210
Study 21350719 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 210
Study 18611062 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 15 mg (hepatic impairment study)
Number of subjects: 38
Study 18611062 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 15 mg (renal impairment study)
Number of subjects: 38
Study 16038680 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (inducing a mild state of glucoprivation)
Number of subjects: 96
Study 16038680 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 96
Study 12509164 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmark condition; route learning with landmarks
Number of subjects: 84
Study 12509164 — intervention group
Group type: COMPARATOR
Intervention: No-Landmark condition; route learning with no landmarks
Number of subjects: 84
Study 10591309 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (Ritalin) hydrochloride at doses of 0.3 mg/kg or 0.6 mg/kg
Number of subjects: 50
Study 10591309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8901800 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (50 mg on alternate days)
Number of subjects: 59
Study 8901800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8901800 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 59
Study 1831585 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus followed by 2.5 micrograms/kg/min maintenance infusion
Number of subjects: 21
Study 1831585 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus followed by 5.0 micrograms/kg/min maintenance infusion
Number of subjects: 21
Study 1831585 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus followed by 10.0 micrograms/kg/min maintenance infusion
Number of subjects: 21
Study 1831585 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 5.0 micrograms/kg/min maintenance infusion without loading dose
Number of subjects: 21
Study 1831585 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups receiving enoximone
Number of subjects: 21
Study 6344645 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratological (OK) treatment
Number of subjects: 0
Study 6344645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31651592 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy
Number of subjects: 310
Study 31651592 — intervention group
Group type: COMPARATOR
Intervention: Office-based placebo therapy
Number of subjects: 310
Study 30630804 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension Group 1 (Group H1)
Number of subjects: 75
Study 30630804 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension Group 2 (Group H2)
Number of subjects: 75
Study 30630804 — intervention group
Group type: COMPARATOR
Intervention: Normal blood pressure Group (Group N)
Number of subjects: 75
Study 26526816 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stents (SES)
Number of subjects: 30
Study 26526816 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus‐eluting stents (EES)
Number of subjects: 30
Study 26526816 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus‐eluting stents (ZES)
Number of subjects: 30
Study 26526816 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 24292216 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope-assisted surgery
Number of subjects: 41
Study 24292216 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 41
Study 24292216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 22426327 — intervention group
Group type: COMPARATOR
Intervention: Human EV71 vaccine (200 U and 400 U for adults and children; 100 U, 200 U, and 400 U for infants); administered intramuscularly on Days 0, 14, and 28 for adults, and Days 0, 28, and 56 for children and infants.
Number of subjects: 0
Study 22426327 — intervention group
Group type: COMPARATOR
Intervention: Placebo; administered in the same schedule as the vaccine.
Number of subjects: 0
Study 18722511 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (preventive antibacterial therapy)
Number of subjects: 80
Study 18722511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18560142 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation system
Number of subjects: 12
Study 18560142 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face assessment
Number of subjects: 12
Study 16104989 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (n=43)
Number of subjects: 83
Study 16104989 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir (n=40)
Number of subjects: 83
Study 12401624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% ropivacaine/fentanyl 5 micro g/mL
Number of subjects: 80
Study 12401624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine/fentanyl 5 micro g/mL
Number of subjects: 80
Study 12401624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 80
Study 12401624 — intervention group
Group type: COMPARATOR
Intervention: IV morphine consumption
Number of subjects: 80
Study 12401624 — intervention group
Group type: COMPARATOR
Intervention: Pain scores (rest and spirometry)
Number of subjects: 80
Study 12401624 — intervention group
Group type: COMPARATOR
Intervention: Motor block
Number of subjects: 80
Study 10405061 — intervention group
Group type: EXPERIMENTAL
Intervention: Delfon
Number of subjects: 10
Study 10405061 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptrol
Number of subjects: 10
Study 10405061 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantage 24
Number of subjects: 10
Study 10405061 — intervention group
Group type: EXPERIMENTAL
Intervention: VCF
Number of subjects: 10
Study 10405061 — intervention group
Group type: EXPERIMENTAL
Intervention: Semicid
Number of subjects: 10
Study 7545449 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 26
Study 7545449 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 26
Study 7545449 — intervention group
Group type: COMPARATOR
Intervention: Titrarine (Stago) and Heptest (Haemachem)
Number of subjects: 26
Study 7545449 — intervention group
Group type: COMPARATOR
Intervention: Thrombin time
Number of subjects: 26
Study 2208619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxibendazole 15mg/kg.d x 3d
Number of subjects: 714
Study 2208619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel 10mg/kg.d x 3d
Number of subjects: 714
Study 2208619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study 6107232 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg iv
Number of subjects: 9
Study 6107232 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg po
Number of subjects: 9
Study 6107232 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (iv and po)
Number of subjects: 9
Study 31692248 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization for data visualization
Number of subjects: 0
Study 31692248 — intervention group
Group type: COMPARATOR
Intervention: High-dimensional analytical tools (dimensionality reduction, clustering, network reconstruction)
Number of subjects: 0
Study 29985762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier transform infrared (FT-IR) analysis
Number of subjects: 75
Study 29985762 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration of FT-IR analysis
Number of subjects: 75
Study 29985762 — intervention group
Group type: COMPARATOR
Intervention: Traditional laboratory X-ray diffraction (XRD) analysis
Number of subjects: 75
Study 26139093 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 min twice a week)
Number of subjects: 116
Study 26139093 — intervention group
Group type: COMPARATOR
Intervention: Reference group (lectures)
Number of subjects: 116
Study 25311600 — intervention group
Group type: COMPARATOR
Intervention: Very early adiposity rebound (AR) (by 3.5 years)
Number of subjects: 546
Study 25311600 — intervention group
Group type: COMPARATOR
Intervention: Early adiposity rebound (AR) (between 3.5 and 5 years)
Number of subjects: 546
Study 22079079 — intervention group
Group type: EXPERIMENTAL
Intervention: 5%, 10%, 15%, or 20% W(80)5EC combined with 4 or 10 μg strain‐specific Fluzone(®) HA
Number of subjects: 199
Study 22079079 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% W(80)5EC combined with 10 μg strain‐specific HA
Number of subjects: 199
Study 22079079 — intervention group
Group type: COMPARATOR
Intervention: Intranasal PBS
Number of subjects: 199
Study 22079079 — intervention group
Group type: COMPARATOR
Intervention: Intranasal Fluzone(®)
Number of subjects: 199
Study 22079079 — intervention group
Group type: COMPARATOR
Intervention: 15 μg strain‐specific intramuscular Fluzone(®)
Number of subjects: 199
Study 20580029 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) - conjugated equine estrogen 0.625 mg/d with or without medroxyprogesterone acetate 2.5 mg/d
Number of subjects: 0
Study 20580029 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 17610100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day CLA plus 2 g/day SFO
Number of subjects: 12
Study 17610100 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day CLA
Number of subjects: 12
Study 17610100 — intervention group
Group type: COMPARATOR
Intervention: 4 g/day safflower oil (SFO)
Number of subjects: 12
Study 15629974 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis (BB-12)
Number of subjects: 201
Study 15629974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Number of subjects: 201
Study 15629974 — intervention group
Group type: COMPARATOR
Intervention: Control (no probiotics)
Number of subjects: 201
Study 12127119 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fundoplication (Nissen-Rossetti)
Number of subjects: 137
Study 12127119 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial fundoplication (Toupet)
Number of subjects: 137
Study 10327507 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Back School
Number of subjects: 43
Study 10327507 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 8578800 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 vaccine in two accelerated schedules (Groups 1 and 2)
Number of subjects: 0
Study 8578800 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 vaccine at 0, 1, 6, and 12 months (Groups 3 and 4)
Number of subjects: 0
Study 1774408 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 1774408 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0
Study 1774408 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of midazolam and alfentanil
Number of subjects: 0
Study 7037105 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of oesophageal varices (group 2)
Number of subjects: 100
Study 7037105 — intervention group
Group type: COMPARATOR
Intervention: Tamponade only (group 1)
Number of subjects: 100
Study 29338151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prolonged-release oxycodone/naloxone (OXN) 10 +10 +5 mg every 12 hours
Number of subjects: 0
Study 29338151 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine patient-controlled analgesia (IVPCA) 2 mg bolus, no basal infusion
Number of subjects: 0
Study 29338151 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine patient-controlled analgesia (IVPCA)
Number of subjects: 0
Study 27670400 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based treatment (ABT)
Number of subjects: 190
Study 27670400 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral treatment (SBT)
Number of subjects: 190
Study 25335250 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothing-liver and regulating-spleen method (Group A)
Number of subjects: 156
Study 25335250 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulating Governor Vessel method (Group B)
Number of subjects: 156
Study 25335250 — intervention group
Group type: COMPARATOR
Intervention: Estazolam tablets (1 mg each day for 30 days) (Group C)
Number of subjects: 156
Study 23986168 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection of 36 Units of AbobotulinumtoxinA (ABO) into the middle of the lateral orbital rhytides
Number of subjects: 40
Study 23986168 — intervention group
Group type: COMPARATOR
Intervention: Three intradermal injections of 12 Units each of AbobotulinumtoxinA (ABO) along the lateral canthal area
Number of subjects: 40
Study 20332416 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18467912 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg) bid and amoxicillin (1000 mg) bid and clarithromycin (500 mg) bid for 1 week, followed by placebo for 3 weeks (EAC and placebo)
Number of subjects: 401
Study 18467912 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg) bid and amoxicillin (1000 mg) bid and clarithromycin (500 mg) bid for 1 week, followed by esomeprazole (20 mg) once daily for 3 weeks (EAC and E20)
Number of subjects: 401
Study 18467912 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (20 mg) once daily for 3 weeks after 1 week of esomeprazole (20 mg) bid and placebo antimicrobials (E20 bid and E20)
Number of subjects: 401
Study 18467912 — intervention group
Group type: EXPERIMENTAL
Intervention: EAC and E20
Number of subjects: 401
Study 18467912 — intervention group
Group type: EXPERIMENTAL
Intervention: EAC and placebo
Number of subjects: 401
Study 18467912 — intervention group
Group type: COMPARATOR
Intervention: E20 bid and E20
Number of subjects: 401
Study 16615116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal supplement containing folic acid and wheat bran fiber (WBF)
Number of subjects: 0
Study 16615116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0
Study 16615116 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin users
Number of subjects: 0
Study 12826544 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 68
Study 12826544 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 68
Study 10944557 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary genetic and surgical assessment service
Number of subjects: 1000
Study 10944557 — intervention group
Group type: COMPARATOR
Intervention: Current service provisions (without genetic assessment)
Number of subjects: 1000
Study 8824962 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder irrigation with amphotericin B
Number of subjects: 109
Study 8824962 — intervention group
Group type: COMPARATOR
Intervention: Oral fluconazole
Number of subjects: 109
Study 1554120 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (10 mg = 1 mL)
Number of subjects: 52
Study 1554120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL Intralipid)
Number of subjects: 52
Study 3916838 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymomodulin (TM), 1 ampoule b.i.d. per os for 30 days
Number of subjects: 50
Study 3916838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30661011 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led stress inoculation training integrated with exercise (n=53)
Number of subjects: 108
Study 30661011 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based exercise alone (n=55)
Number of subjects: 108
Study 28575484 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (transfusion trigger < 10 g/dL, Group 1)
Number of subjects: 160
Study 28575484 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (transfusion trigger ≤ 7 g/dL, Group 2)
Number of subjects: 160
Study 26563117 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g L-arginine supplementation
Number of subjects: 8
Study 26563117 — intervention group
Group type: COMPARATOR
Intervention: Control (no L-arginine supplementation)
Number of subjects: 8
Study 24714783 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-applied characterized autologous cultured chondrocytes (MACI)
Number of subjects: 144
Study 24714783 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MFX)
Number of subjects: 144
Study 22614148 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g·d⁻¹ CLA
Number of subjects: 10
Study 22614148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20456751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin (3500 IU subcutaneously once daily for 8 days, followed by bemiparin for 20 additional days)
Number of subjects: 625
Study 20456751 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after initial 8 days of bemiparin)
Number of subjects: 625
Study 20456751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 625
Study 20456751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study 18947359 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot group (high-craving first session)
Number of subjects: 98
Study 18947359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold group (low-craving first session)
Number of subjects: 98
Study 18947359 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (experienced high-craving session only)
Number of subjects: 98
Study 15592872 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG(4) antibodies to mink and silver fox urine
Number of subjects: 387
Study 15592872 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive skin prick tests to fur urine allergens
Number of subjects: 387
Study 15592872 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG(4) levels
Number of subjects: 387
Study 15592872 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG(4) antibodies
Number of subjects: 387
Study 11846201 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucogingival bilaminar technique (BT)
Number of subjects: 45
Study 11846201 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 45
Study 11846201 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined periodontal regenerative technique (CPRT)
Number of subjects: 45
Study 10025425 — intervention group
Group type: EXPERIMENTAL
Intervention: AD+DLB
Number of subjects: 160
Study 10025425 — intervention group
Group type: COMPARATOR
Intervention: pure AD
Number of subjects: 160
Study 7793402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone (mean maintenance dose 268 ± 100 mg/day)
Number of subjects: 110
Study 1323545 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA), 75 mg sustained release
Number of subjects: 101